— Know what they know.
Not Investment Advice

EWTX NASDAQ

Edgewise Therapeutics, Inc.
1W: -3.9% 1M: +1.6% 3M: +11.5% YTD: +37.6% 1Y: +119.8% 3Y: +249.2% 5Y: +18.0%
$32.70
+0.01 (+0.03%)
 
Weekly Expected Move ±11.8%
$25 $29 $33 $37 $41
NASDAQ · Healthcare · Biotechnology · Alpha Radar Neutral · Power 44 · $3.5B mcap · 78M float · 1.32% daily turnover · Short 56% of daily vol

Cash Flow Trends

Operating Cash Flow
-$144M -31.9% ▼
Capital Expenditures
$256K +80.5% ▲
5Y CAGR: +4.7%
Free Cash Flow
-$144M -30.3% ▼
Dividends Paid
$0 +0.0% ▲
Buybacks
$0 +0.0% ▲
Net Change in Cash
$19M +143.8% ▲

Cash Flow Composition

Year-over-Year Growth

View Full Cash Flow Statement
Line ItemFY2021FY2022FY2023FY2024FY2025
— Operating Activities —
Net Income-$43M-$68M-$100M-$134M-$168M
Depreciation & Amort.$272K$538K$2M$2M$2M
Stock-Based Comp.$4M$11M$18M$25M$0
Change in Working Capital$5M$4M-$2M$10M-$5M
Other Non-Cash Items$2M-$543K-$10M-$13M$27M
Operating Cash Flow-$34M-$53M-$92M-$109M-$144M
— Investing Activities —
Capital Expenditures-$668K-$6M-$6M-$1M-$256K
Acquisitions (Net)$242K$65K$0$0$0
Investment Purchases-$288M-$292M-$256M-$477M-$527M
Investment Sales$47M$227M$364M$294M$495M
Other Investing-$242K-$65K$0$0$0
Investing Cash Flow-$242M-$71M$103M-$185M-$33M
— Financing Activities —
Net Debt Issuance$0$0$0$0$0
Stock Repurchased$0$0$0$0$0
Dividends Paid$0$0$0$0$0
Other Financing$236K$474K$548K$10M$0
Financing Cash Flow$186M$130M$53M$249M$196M
Net Change in Cash-$89M$6M$64M-$44M$19M
Cash End of Period$16M$22M$86M$42M$61M
Free Cash Flow-$34M-$58M-$98M-$110M-$144M

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms